NSGC practice guideline: Risk assessment and genetic counseling for hereditary breast and ovarian cancer

Journal of Genetic Counseling

Volumn 22, Issue 2, 2013, Pages 155-163

  Berliner, Janice L ^a   Fay, Angela Musial ^b   Cummings, Shelly A ^c   Burnett, Brittany ^d   Tillmanns, Todd ^e  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MERIDIAN HEALTH SYSTEM   (United States)

^c Myriad Genetic Laboratories   (United States)

^d SHARP HEALTHCARE   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

BRCA1; BRCA2; Cancer genetic counseling; Hereditary breast and ovarian cancer; Medical management; Risk assessment

Indexed keywords

BREAST NEOPLASMS; FEMALE; GENETIC COUNSELING; GENETIC SCREENING; GENETICS; HUMAN; OVARIAN NEOPLASMS; PRACTICE GUIDELINE; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE; ARTICLE; BREAST TUMOR; OVARY TUMOR;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; GENETIC TESTING; HUMANS; OVARIAN NEOPLASMS; RISK ASSESSMENT;

EID: 84879692727     PISSN: 10597700     EISSN: 15733599     Source Type: Journal    
DOI: 10.1007/s10897-012-9547-1     Document Type: Article

References (56)

1. ACOG Committee on Practice Bulletins. Hereditary breast and ovarian cancer syndrome (2009) Gynecologic Oncology, 113(1), 6-11.
2. ACOG Practice Bulletin No. 103: Hereditary Breast and Ovarian Cancer Syndrome (2009). Obstetrics and Gynecology, 113(4), 957-966.
3. Alter, B. P.; Rosenberg, P. S.; & Brody, L. C. (2007). Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. Journal of Medical Genetics, 44(1), 1-9.
4. American College of Medical Genetics and Genomics. (2012). Policy statement: points to consider in the clinical application of genomic sequencing. Genetics in Medicine, 14(8), 759-761.
5. American Society of Clinical Oncology. (2003). American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. Journal of Clinical Oncology, 21, 2397-2406.
6. American Society of Clinical Oncology. (2010). American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology, 28, 893-901.
7. Americans with Disabilities Act of 1990; www.ada.gov/pubs/ada.htm.
8. Antoniou, A. C.; Pharoah, P. D.; McMullan, G.; Day, N. E.; Stratton, M. R.; Peto, J.; et al. (2002). A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. British Journal of Cancer, 86(1), 76-83.
9. Antoniou, A.; Pharoah, P. D.; Narod, S.; Risch, H. A.; Eyfjord, J. E.; Hopper, J. L.; et al. (2003). Average risks of breast and ovarian cancer associated with BRCA1 and BRCA2 mutations detected in cases series unselected for family history: a combined analysis of 22 studies. American Journal of Human Genetics, 72(5), 1117-1130.
10. Antoniou, A. C.; Pharoah, P. D.; Smith, P.; & Easton, D. F. (2004). The BOADICEA model of genetic susceptibility to breast and ovarian cancer. British Journal of Cancer, 91(8), 1580-1590.
11. Armstrong, K.; Eisen, A.; & Weber, B. (2000). Assessing the risk of breast cancer. The New England Journal of Medicine, 342(8), 564-571.
12. Atchley, D. P.; Albarracin, C. T.; Lopez, A.; Valero, V.; Amos, C. I.; Gonzalez-Angulo, A. M.; Hortobagyi, G. N.; & Arun, B. K. (2008). Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. Journal of Clinical Oncology, 26, 4282-4288.
13. Begg, C. B.; Haile, R. W.; Borg, A.; Malone, K. E.; Concannon, P.; et al. (2009). Variation of breast cancer risk among BRCA1/2 carriers. An investigation by the WECARE Study Group. JAMA, 299(2), 194-201.
14. Beiner, M. E.; Finch, A.; Rosen, B.; Lubinski, J.; Moller, P.; Ghadirian, P.; et al. (2007). The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecologic Oncology, 104, 7-10.
15. Bergman, A.; Einbeigi, Z.; Olofsson, U.; Taib, Z.; Wallgren, A.; Karlsson, P.; et al. (2001). The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation. European Journal of Human Genetics, 9, 787-793.
16. Berliner, J. L.; & Fay, A. M. (2007). Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. Journal of Genetic Counseling, 16(3), 241-260.
17. Berry, D. A.; Parmigiani, G.; Sanchez, J.; Schildkraut, J.; & Winer, E. (1997). Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. Journal of the National Cancer Institute, 89(3), 227-238.
18. Bevers, T. B.; Anderson, B. O.; Bonaccio, E.; Buys, S.; Daly, M. B.; Dempsey, P. J.; et al. (2009). Breast cancer screening and diagnosis. JNCCN, 7, 1060-1096.
19. Chen, S.; Iversen, E. S.; Friebel, T.; Finkelstein, D.; et al. (2006). Characterization of BRCA1 and BRCA2 mutations in a large United States sample. Journal of Clinical Oncology, 24(6), 863-871.
20. Claus, E.; Risch, N.; & Thompson, D. (1994). Autosomal dominant inheritance of early-onset breast cancer. Cancer, 73, 643-651.
21. Csokay, B.; Udvarhelyi, N.; Sulyok, Z.; Besznyak, I.; Ramus, S.; Ponder, B.; et al. (1999). High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Research, 59, 995-998.
22. Edwards, S. M.; Evans, D. G.; Hope, Q.; Norman, A. R.; Barbachano, Y.; Bullock, S.; et al. (2010). Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. British Journal of Cancer, 103(6), 918-924.
23. Fasouliotis, S. J.; & Schenker, J. G. (2000). BRCA1 and BRCA2 gene mutations: decision-making dilemmas concerning testing and management. Obstetrical & Gynecological Survey, 55(6), 373-384.
24. Gail, M. H.; Brinton, L. A.; Byar, D. P.; Corle, D. K.; Green, S. B.; Schairer, C.; et al. (1989). Projecting individualized probabilities of developing breast cancer for white females who are being examine annually. Journal of the National Cancer Institute, 81, 1879-1886.
25. GeneTests (2012). http://www.genetests.org.
26. Godard, B.; Foulkes, W. D.; Provencher, D.; Brunet, J. S.; Tonin, P. N.; Mes-Masson, A. M.; et al. (1998). Risk factors for familial and sporadic ovarian cancer among French Canadians: a case-control study. American Journal of Obstetrics and Gynecology, 179(2), 403-410.
27. Gonzalez-Angulo, A. M.; Timms, K. M.; Liu, S.; Chen, H.; Litton, J. K.; Potter, J.; et al. (2011). Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clinical Cancer Research, 17(5), 1082-1089.
28. Greely, H. T. (2005). Banning genetic discrimination. NEJM, 353(9), 865-867.
29. Health Insurance Portability and Accountability Act of 1996, Pub L No 104-191; US Department of Health and Human Services: OCR Privacy Brief. Summary of the HIPAA Privacy Rule. http://www.hhs.gov/ocr/privacysummary.pdf.
30. H.R. 493 (110th): Genetic Information Nondiscrimination Act of 2008, accessed at http://www.govtrack.us/congress/bills/110/hr493.
31. Kauff, N. D.; Mitra, N.; Robson, M. E.; Hurley, K. E.; Chuai, S.; Goldfrank, D.; et al. (2005). Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. JNCI, 97(18), 1382-1384.
32. Lavie, O.; Ben-Arie, A.; Segev, Y.; Faro, J.; Barak, F.; Haya, N.; Auslender, R.; & Gemer, O. (2010). BRCA germline mutations in women with uterine serous carcinoma-still a debate. International Journal of Gynecological Cancer, 20(9), 1531-1534.
33. Lindor & Greene (2008). SPECIAL ARTICLE. The Concise Handbook of Family Cancer Syndromes. Journal of the National Cancer Institute Monographs, No. 38.
34. Lowery, M.; Kelsen, D.; Stadler, Z.; Yu, K. H.; Janjigian, Y. Y.; Ludwig, E.; et al. (2011). An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. The Oncologist, 16, 1397-1402.
35. Metcalfe, K.; Lynch, H. T.; Ghadirian, P.; Tung, N.; Olivotto, I.; Warner, E.; et al. (2004). Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Journal of Clinical Oncology, 22(12), 2328-2335.
36. Metcalfe, K. A.; Lynch, H. T.; Ghadirian, P.; Tung, N.; Olivotto, I. A.; Foulkes, W. D.; et al. (2005). The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecologic Oncology, 96(1), 222-226.
37. Metcalfe, K. A.; Finch, A.; Poll, A.; Horsman, D.; Kim-Sing, C.; & Scott, J. (2009). Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation. British Journal of Cancer, 100(2), 421-425.
38. Mikaelsdottir, E. K.; Valgeirsdottir, S.; Eyfjord, J. E.; & Rafnar, T. (2004). The Icelandic founder mutation BRCA2 999del5: analysis of expression. Breast Cancer Research, 6, R284-R290.
39. Narod, S. A.; Neuhausen, S.; Vichodez, G.; Armel, S.; Lynch, H. T.; Ghadirian, P.; et al. (2008). Rapid progression of prostate cancer in men with a BRCA2 mutation. British Journal of Cancer, 99(2), 371-374.
40. National Cancer Institute (2009). Breast Cancer Prevention. Description of Evidence. http://www.cancer.gov/cancertopics/pdq/genetics/breast-and ovarian/HealthProfessional#Section-6
41. National Comprehensive Cancer Network (NCCN) Guidelines, Inc. (2012). Hereditary Breast and/or Ovarian Cancer Syndrome (v.3.2012). http://www.nccn.org/professionals/physician-gls/pdf/genetics-screening.pdf
42. National Society of Genetic Counselors (NSGC) Code of Ethics (adopted 1/92; revised 1/06) http://www.nsgc.org/Advocacy/NSGCCodeofEthics/tabid/155/ Default.aspx
43. Parmigiani, G.; Berry, D.; & Aguilar, O. (1998). Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. American Journal of Human Genetics, 62, 145-158.
44. Patenaude, A. F. (2005). Genetic testing for cancer: Psychological approaches for helping patients and families. Washington, DC: American Psychological Association.
45. Petrij-Bosch, A.; Peelen, T.; van Vliet, M.; van Eijk, R.; Olmer, R.; Drüsedau, M.; et al. (1997). BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nature Genetics, 17, 341-345.
46. Riley, B. D.; Culver, J. O.; Skrzynia, C.; Senter, L. A.; Peters, J. A.; Costalas, J. W.; et al. (2012). Essential elements of genetic cancer risk assessment, counseling and testing: updated recommendations of the National Society of Genetic Counselors. Journal of Genetic Counseling, 21(2), 151-161.
47. Roa, B. B.; Boyd, A. A.; Volcik, K.; & Richards, C. S. (1996). Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nature Genetics, 14(2), 185-187.
48. Saslow, D.; Boetes, C.; Burke, W.; et al. (2007). American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA: A Cancer Journal for Clinicians, 57(57), 75-89.
49. Society of Gynecologic Oncologists Education Committee Statement on Risk Assessment for Inherited Gynecological Cancer Predispositions. (2007) Gynecologic Oncology, 107, 159-162.
50. Stopfer, J. E. (2000). Genetic counseling and clinical cancer genetics services. Seminars in Surgical Oncology, 18, 347-357.
51. Tai, Y. C.; Domchek, S.; Parmigiani, G.; & Chen, S. (2007). Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. JNCI, 99(23), 1811-1814.
52. Thompson, D.; Easton, D. F.; & Breast Cancer Linkage Consortium. (2002). Cancer incidence in BRCA1 mutation carriers. JNCI, 94(18), 1358-1365.
53. Tonin, P. N.; Mes-Masson, A. M.; Futreal, P. A.; Morgan, K.; Mahon, M.; Foulkes, W. D.; et al. (1998). Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. American Journal of Human Genetics, 63, 1341-1351.
54. Tyrer, J.; Duffy, S.; & Cuzick, J. (2004). A breast cancer prediction model incorporating familial and personal risk factors. Statistics in Medicine, 23, 1111-1130.
55. U.S. Preventive Services Task Force. (2005). Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: Recommendation statement. Annals of Internal Medicine, 143(5), 355-361.
56. van Asperen, C. J.; Brohet, R. M.; Meijers-Heijboer, E. J.; Hoogerbrugge, N.; Verhoef, S.; Vasen, H. F.; et al. (2005). Netherlands Collaborative Group on Hereditary Breast Cancer (HEBON). Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. Journal of Medical Genetics, 42(9), 711-719.